A review on cardiovascular effects of newer hypoglycaemic medications

References

• Centers for Disease Control and Prevention. National Diabetes Statistics Report: estimates of diabetes and its burden in the United States. Atlanta, GA: US Department of Health and Human Services; 2014.
   Google Scholar
• Matheus A, Tannus L, Cobas R, et al. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013;2013:1–15.
   Google Scholar
• Nichols G, Gullion C, Koro C, et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27:1879–1884.
   PubMed Web of Science ®Google Scholar
• Gustafsson I, Brendorp B, Seibæk M, et al. Influence of diabetes and diabetes–gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol. 2004;43:771–777.
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. 1998;352:854–865.
   PubMed Web of Science ®Google Scholar
• Holman R, Paul S, Bethel M, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139.
   PubMed Web of Science ®Google Scholar
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
   PubMed Web of Science ®Google Scholar
• Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559.
   PubMed Web of Science ®Google Scholar
• A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: I. Design, methods and baseline results. University Group Diabetes Program. Diabetes. 1970;19:747–783.
   Web of Science ®Google Scholar
• Pharmacologic approaches to glycemic treatment. Diabetes Care. 2016;40:S64–S74.
   Web of Science ®Google Scholar
• Garber A, Abrahamson M, Barzilay J, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary. Endocr Pract. 2017;23:207–238.
   PubMed Web of Science ®Google Scholar
• A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes. 1976;25:1129–1153.
   PubMed Web of Science ®Google Scholar
• UKPDS 33 – intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2012;36:1304–1311.
   PubMed Web of Science ®Google Scholar
• Nissen S, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke Y, Furberg C. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298:1189.
   PubMed Web of Science ®Google Scholar
• Home P, Pocock S, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. The Lancet. 2009;373:2125–2135.
   PubMed Web of Science ®Google Scholar
• FDA 2008 Statement – U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet]. Silver Spring: U.S. Food and Drug Administration; 2008; [cited 29 Apr 2017]. Available from: https://www.fda.gov/downloads/Drug/GuidanceComplianceRegulatoryInformation/%20Guidances/ucm071627.psd
   Google Scholar
• EMA 2012 guideline – guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus [Internet]; 2012 [cited 30 Apr 2017]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf
   Google Scholar
• Mahaffey K, Hafley G, Dickerson S, et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J. 2013;166:240.e1–249.e1.
   Web of Science ®Google Scholar
• Rosiglitazone REMS statement – FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines [Internet]. Fda.gov; 2017; [cited 29 Apr 2017]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm376389.htm
   Google Scholar
• Dormandy J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. The Lancet. 2005;366:1279–1289.
   PubMed Web of Science ®Google Scholar
• Kernan W, Viscoli C, Furie K, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321–1331.
   PubMed Web of Science ®Google Scholar
• Nissen S, Nicholls S, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561.
   PubMed Web of Science ®Google Scholar
• Gregg E, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370:1514–1523.
   PubMed Web of Science ®Google Scholar
• Tancredi M, Rosengren A, Svensson A, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373:1720–1732.
   PubMed Web of Science ®Google Scholar
• Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376:1407–1418.
   PubMed Web of Science ®Google Scholar
• Drucker D. The role of gut hormones in glucose homeostasis. J Clin Invest. 2007;117:24–32.
   PubMed Web of Science ®Google Scholar
• Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012;344:e1369.
   PubMed Web of Science ®Google Scholar
• Kawalec P, Mikrut A, Łopuch S. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2014;30:269–283.
   PubMed Web of Science ®Google Scholar
• Yousefzadeh P, Wang X. The effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks in type 2 diabetes mellitus. J Diabetes Res. 2013;2013:1–6.
   Web of Science ®Google Scholar
• Zannad F, Cannon C, Cushman W, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. The Lancet. 2015;385:2067–2076.
   PubMed Web of Science ®Google Scholar
• Scirica B, Bhatt D, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• White W, Cannon C, Heller S, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
   PubMed Web of Science ®Google Scholar
• Green J, Bethel M, Armstrong P, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• Savarese G, Perrone-Filardi P, D'Amore C, et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-analysis. Int J Cardiol. 2015;181:239–244.
   PubMed Web of Science ®Google Scholar
• Wu S, Hopper I, Skiba M, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014;32:147–158.
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metabol Cardiovasc Dis. 2014;24:689–697.
   PubMed Web of Science ®Google Scholar
• Clifton P. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure? Clin Ther. 2014;36:2072–2079.
   PubMed Web of Science ®Google Scholar
• Li L, Li S, Deng K, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ. 2016;352:i610.
   PubMed Web of Science ®Google Scholar
• Page R, O’Bryant C, Cheng D, et al. Drugs that may cause or exacerbate heart failure. Circulation. 2016;134:e32–e69.
   PubMed Web of Science ®Google Scholar
• Pfeffer M, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar
• Marso S, Daniels G, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Marso S, Bain S, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol. 2015;14:142.
   PubMed Web of Science ®Google Scholar
• Basile J. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complicat. 2013;27:280–286.
   PubMed Web of Science ®Google Scholar
• Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin J, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes [Internet]. Fda.gov; 2017 [cited 12 Feb 2017]. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm531517.htm
   Google Scholar
• Jardiance® (empagliflozin) becomes first type 2 diabetes medicine in the EU to include cardiovascular death reduction data in label [Internet]. Boehringer-ingelheim.com; 2017 [cited 6 May 2017]. Available from: https://www.boehringer-ingelheim.com/press-release/jardiance-cardiovascular-death-eu-label-update
   Google Scholar
• CANVAS – CANagliflozin cardioVascular Assessment Study – Full Text View – ClinicalTrials.gov [Internet]. Clinicaltrials.gov; 2017 [cited 9 May 2017]. Available from: https://clinicaltrials.gov/ct2/show/NCT01032629
   Google Scholar
• Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events – full text view – ClinicalTrials.gov [Internet]. Clinicaltrials.gov; 2017 [cited 9 May 2017]. Available from: https://clinicaltrials.gov/ct2/show/NCT01730534
   Google Scholar
• Onglyza® (saxagliptin) [package insert on the Internet]. Wilmington (DE): AstraZeneca; 2017 [revised 2017 Feb; cited 2017 Mar 13]. Available from: http://www.azpicentral.com/onglyza/pi_onglyza.pdf#page =1
   Google Scholar
• CAROLINA: cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes – full text view – ClinicalTrials.gov [Internet]. Clinicaltrials.gov; 2017 [cited 13 Mar 2017]. Available from: https://clinicaltrials.gov/ct2/show/NCT01243424
   Google Scholar
• Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus – full text view – ClinicalTrials.gov [Internet]. Clinicaltrials.gov; 2017 [cited 29 Mar 2017]. Available from: https://clinicaltrials.gov/ct2/show/NCT01144338
   Google Scholar
• Effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in subjects with type 2 diabetes mellitus – full text view – ClinicalTrials.gov [Internet]. Clinicaltrials.gov; 2017 [cited 29 Mar 2017]. Available from: https://clinicaltrials.gov/ct2/show/NCT02465515
   Google Scholar
• Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) – full text view – ClinicalTrials.gov [Internet]. Clinicaltrials.gov; 2017 [cited 29 Mar 2017]. Available from: https://clinicaltrials.gov/ct2/show/NCT01394952
   Google Scholar
• Invokana® (canagliflozin) [package insert on the Internet]. Titusville (NJ): Janssen; 2013 [revised 2016 July; cited 2017 Feb 11]. Available from: https://www.invokana.com/prescribing-information.pdf
   Google Scholar
• Jardiance® (empagliflozin) [package insert on the Internet]. Ridgefield (CT): Boehringer Ingelheim; 2014 [revised 2016 Dec; cited 2017 Feb 11]. Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf
   Google Scholar
• Farxiga® (dapagliflozin) [package insert on the Internet]. Wilmington (DE): AstraZeneca; 2014 [revised 2016 July; cited 2017 Feb 11]. Available from: http://www.azpicentral.com/farxiga/pi_farxiga.pdf#page =1
   Google Scholar
• DeFronzo R, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2016;13:11–26.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
   PubMed Web of Science ®Google Scholar